|
|
 |
|
Viewing report
|
|
|
|
Czech Republic Pharmaceuticals and Healthcare Report Q1 2009
Business Monitor International, Feb 2009, Pages: 72
Czech Republic Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Czech Republic's pharmaceuticals and healthcare industry.
The Czech Republic sits on top of the Business Environment Rankings for Q109 for Central and Eastern Europe. Scoring an equal overall score to neighbouring Slovakia, the Czech market demonstrates a reasonable size by regional standards, high per capita spending and good growth prospects. Despite the negative pricing and reimbursement regulations in the country, sound demographic, political and economic scores mean the country fairs well compared to its regional peers.
Per capita spending on pharmaceuticals reached US$365 in 2008. This signifies the Czech population’s growing access to innovative treatments. Nevertheless, the generics and over-the-counter (OTC) sectors are likely to gain an increased market share in the future, as the government looks to create cost efficiencies within the healthcare system. We have extended our forecasts through to 2013, and forecasts that total drug expenditure will reach US$5.5bn by the end of the forecast period, growing at an average of 5.8% year-on-year (y-o-y) in local currency terms.
Pharmaceutical prices in the Czech Republic are set to significantly decline throughout 2009, as the implementation of pricing and reimbursement reforms will introduce a dual referencing system. The use of jumbo reference groups – which can effectively place patented pharmaceuticals in the same category as similar generic therapeutics – may result in significant reductions for all but the most innovative new products.
The first set of drugs to be referenced were angiotensin-converting enzyme inhibitors (ACEi's) and angiotensin receptor blockers (ARBs), as these classes of drugs have the biggest potential for savings. It is expected that statins, proton-pump inhibitors (PPIs) and H2 receptor antagonists will follow, with all other reference groups due to be included by the end of 2008.
Healthcare fees continue to be the cause of controversy in the political arena, and even led to serious destabilisation of the government’s position following regional elections in the latter part of 2008. The opposition CSSD has threatened to subsidise fees in regional hospitals which could seriously compromise sales of prescription drugs in the outpatient sector.
In late 2008, Health Minister Tomas Julinek began devising further reforms to the healthcare system. Potential changes to the system, likely to be introduced in March 2009, include patients being allowed to seek a second opinion for medical conditions, with costs being covered by the state health insurance and the sale or lease of doctors’ practices. Plans to transform health insurance companies and future university hospitals into joint stock companies have been opposed by opposition parties.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
OTC Healthcare in the Czech Republic to 2010
Analgesics in the Czech Republic
The Pharmaceutical Market: Czech Republic
Pharmaceutical Industry in Czech Republic
Czech Republic Pharmaceuticals & Healthcare Report Q1 2008
Czech Republic Pharmaceuticals and Healthcare Report Q3 2007
Czech Republic Pharmaceuticals and Healthcare Report Q4 2009
Czech Republic Pharmaceuticals and Healthcare Report Q4 2008
Czech Republic Pharmaceuticals and Healthcare Report Q3 2009
Czech Republic Pharmaceuticals and Healthcare Report Q2 2009
Czech Republic Pharmaceuticals and Healthcare Report Q2 2008
Czech Republic Pharmaceuticals and Healthcare Report Q3 2008
|
|
|
|
